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A B S T R A C T
Background: Cerebellar liponeurocytoma is an extremely rare tumour entity of the central nervous system. It is
histologically characterised by prominent neuronal/neurocytic differentiation with focal lipidisation and cor-
responding histologically to WHO grade II. It typically develops in adults, and usually shows a low proliferative
potential. Recurrences have been reported in almost 50% of cases, and in some cases the recurrent tumour may
display increased mitotic activity and proliferation index, vascular proliferations and necrosis. Thus pathological
diagnosis of liponeurocytoma is challenging. This case presentation highlights the main clinical, radiographic
and pathological features of a cerebellar liponeurocytoma.
Case presentation: A 59-year-old, right-handed woman presented at our department with a short history of
persistent headache, vertigo and gait disturbances. Examination at presentation revealed that the patient was
awake, alert and fully oriented. The cranial nerve status was normal. Uncertainties were noted in the bilateral
finger-to-nose testing with bradydiadochokinesis on both sides. Strength was full and no pronator drift was
observed. Sensation was intact. No signs of pyramidal tract dysfunction were detected. Her gait appeared in-
secure. The patient underwent surgical resection. Afterward no further disturbances could be detected.
Conclusions: To date> 40 cases of liponeurocytoma have been reported, including cases with supratentorial
location. A review of the 5 published cases of recurrent cerebellar. Liponeurocytoma revealed that the median
interval between the first and second relapse was rather short, indicating uncertain malignant potential. The
most recent WHO classification of brain tumours (2016) classifies the cerebellar liponeurocytoma as a separate
entity and assigns the tumour to WHO grade II. Medulloblastoma is the most important differential diagnosis
commonly seen in children and young adults. In contrast, cerebellar liponeurocytoma is typically diagnosed in
adults. The importance of accurate diagnosis should not be underestimated especially in the view of possible
further therapeutic interventions and for the determination of the patient's prognosis.
1. Background
Cerebellar liponeurocytoma (cLNC) is a rare tumour entity of the
central nervous system. It histologically characterised by prominent
neuronal/neurocytic differentiation with focal lipidisation and corre-
sponding to WHO grade II [1]. It typically develops in adults, and
usually shows a low proliferative potential. Recurrences have been re-
ported in almost 50% of cases, and in some cases the recurrent tumour
may display an increased mitotic activity and proliferation index, vas-
cular proliferations and necrosis [2]. To date< 50 cases of liponeur-
ocytoma have been reported, including cases with supratentorial loca-
tion [3]. A review of the 5 published cases of recurrent cLNC revealed
that the median interval between the first and second relapse was ra-
ther short, indicating a possible malignant progression [2]. The stan-
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dard of care for treating cLNC is surgical resection followed by neu-
roimaging at regular intervals. Specific adjuvant therapies are not im-
plemented.
2. Case presentation
2.1. History
A 59-year-old, right-handed woman presented at our department
with a short history of persistent headache, vertigo and gait dis-
turbances. Physical examination revealed that the patient was awake,
alert and fully oriented. The cranial nerve status was normal.
Uncertainties were noted in the bilateral finger-to-nose testing with
bradydiadochokinesis on both sides. Strength was full and no pronator
drift was observed. Sensation was intact. No signs of pyramidal tract
dysfunction were detected. Her gait appeared unsteady. Magnetic re-
sonance imaging (MRI) was obtained and confirmed a midline in-
traaxial tumour involving the inferior cerebellar vermis. The lesion was
inhomogenously hypointense on the T1-weighted and hyperintense on
the T2-weighted sequence with positive gadolinium (Gd) enhancement
[Fig. 1a–d] and with minimal surrounding edema. Massive mass effect
was evident by compressing the fourth ventricle with mild obstructive
hydrocephalus.
2.2. Surgery and early post-operative MRI
The tumour was completely resected via a median suboccipital
craniotomy. It was well-circumscribed, moderately vascularised and
originated within the medial aspect of the inferior cerebellar vermis.
The fourth ventricle did not have to be opened. The early postoperative
MRI did not detect any tumour remnants [Fig. 2]. Cerebrospinal fluid
pathways were restored.
The patient recovered well from the operation. Slight gait dis-
turbances were noticeable. To this date, 3 years after the operation,
serial neuroimaging did not detect a tumour relapse [Fig. 4a–d].
2.3. Histopathological and molecular data
Neuropathological examination revealed a prominent neuronal
differentiation with focal accumulation of adipocytic cells [Fig. 3a and
b]. The neurocytic areas expressed neuronal markers (e.g. synapto-
physin), GFAP was focally positive [Fig. 3c and d] and Ki-67 was widely
low (5%) [Fig. 3 inset].The routine molecular analyses showed a wild-
type sequence for the IDH1 and IDH2 gene, a preserved ATRX nuclear
expression, a negative 1p19q codeletion status and an unmethylated
MGMT-promoter. Molecular classification by DNA Methylation Pro-
filing was performed by the national competence center for gliomas for
scientific reasons and to exclude a high grade glioma. The 450-K ana-
lysis revealed a high consensus score with the group of cerebellar li-
poneurocytoma and confirmed the diagnosis [Fig. 3e]. For this ex-
perimental analysis, the genome-wide DNA methylation profile is
compared with>1500 tumours of a tumour bank.
3. Discussion and conclusion
cLNC is a rare tumour entity of the central nervous system and ty-
pically diagnosed in adults. Medulloblastoma (MB) is the most im-
portant differential diagnosis often presented as an intraaxial tumour
with close contact to the fourth ventricle. In contrast MB is commonly
seen in children and young adults [4]. Histologically, MB has a more
primitive or embryonal appearance than the neurocytic morphology
observed in the cLNC [4]. Clear cell morphology and lipidised cells are
Fig. 1. The T1-weighted coronal sequence (a) shows an inhomogenously hypointense midline tumour of the posterior fossa. T1-hyperintense signal indicating fatty
content was not detected. The lesion enhances gadolinium inhomogenously (b, c). Note the hyperintense signal of the tumour on T2-weighted sequence (d) and the
regressively altered portions with almost fluid-equivalent T2 and T1 signal.
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not typical findings in MB, but are seen in cLNC. “Generally the Ki-67
proliferation index for cLNC is significantly lower than that for MB and
other high grade mimics, typically< 5%” [4,5]. Unlike astrocytic tu-
mours, an IDH1 mutation is not commonly present in cLNC and there
was no IDH1 mutation detected in the case presented here. A preserved
ATRX nuclear expression and an unmethylated MGMT-promoter do not
exclude a high grad glioma. But in combination with a widely low Ki 67
is not consistent with a high grade glioma. The negative 1p19q code-
letion status excludes an oligodendroglioma.
The adipose tumour cells in MB may also show a typical clustering
comparable to cLNC. However, a growth fraction of 15–40% is not
consistent with newly diagnosed cLNC knowing the fact that pro-
liferative indices of up to 20% were only found in very few primary and
recurrent liponeurocytoma [4]. In addition, genetic analysis revealed
cLNC as a distinct tumour entity without a relation to MB [1].
Central neurocytomas (cN) are typically located supratentorial in
the lateral ventricles and/or in the third ventricle. Histologically they
also correspond to WHO grade II. However, in contrast to these tu-
mours, cLNC are mutated in TP53, indicating that their development is
regulated by different signaling pathways [1].
The importance of an accurate diagnosis should not be under-
estimated, since misdiagnosis could lead to wrong decisions concerning
further therapeutic strategies. There is no need for a change of the
current diagnostic standards. But in case of doubt a reference diagnosis
is of elementary importance. Molecular classification by DNA methy-
lation-profiling may be helpful and accelerates the confirmation of the
diagnosis considering the fact that more common differential diagnosis
like oligodendrogliomas, clear cell ependymomas, or especially high-
grade tumours like medulloblastomas need to be adjuvantly treated
more aggressively.
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Fig. 2. The early postoperative MRI scan shows no evidence of enhancing or non-enhancing residual tumour. A midline resection defect with some air inclusions can
be appreciated.
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Fig. 3. a, b: Tumour sample of liponeurocytoma composed widely of a uniform population of small neurocytic cells with regular round to oval nuclei and focal
accumulation of lipid-laden cells (H&E staining, 100×). Strong and diffuse expression of synaptophysin (c) and focal of GFAP (d), low Ki-67 proliferation index
(inset). Molecular Classification by DNA Methylation Profiling DKFZ Heidelberg (e).
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Fig. 4. MRI follow-up three years after resection. There are no evidences for tumour relapse.
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